Global Syndromic Multiplex Diagnostic Market, By Product and Services (Reagents & Consumables, Instruments, Software & Accessories, Services), Infection Type (Viral, Bacterial, Parasites, Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis, Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel, Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes, Others) - Industry Trends and Forecast to 2031.
Syndromic Multiplex Diagnostic Market Analysis and Size
Syndromic multiplex diagnostics offer the simultaneous testing of multiple pathogens, enabling healthcare professionals to quickly identify the cause of infections. The market is propelled by the rising incidence of infectious diseases, the need for prompt diagnosis in emergency settings, and the growing awareness about the benefits of multiplex testing in guiding appropriate treatment decisions. The integration of molecular diagnostics and syndromic testing approaches is anticipated to further enhance the capabilities of these diagnostic tools, fostering market growth in the coming years.
Data Bridge Market Research analyzes that the global syndromic multiplex diagnostic market which was USD 2.52 billion in 2023, is likely to reach USD 5.05 billion by 2031, and is expected to undergo a CAGR of 6.1% during the forecast period. “Reagent and consumables" dominates the product and services segment of the market due to increasing awareness of proper diagnostics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Syndromic Multiplex Diagnostic Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product and Services (Reagents & Consumables, Instruments, Software & Accessories, Services), Infection Type (Viral, Bacterial, Parasites, Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis, Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel, Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa
|
|
Market Players Covered
|
BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Bosch Healthcare Solutions GmbH (A Subsidiary Of Robert Bosch GmbH) (Germany), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanomix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany), MiRXES Pte Ltd (Singapore)
|
|
Market Opportunities
|
|
Market Definition
Syndromic multiplex diagnostic is a type of advanced diagnostic test utilized to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. The syndromic multiplex diagnostic also helps clinics or hospitals to detect the symptoms and signs of the various types of diseases. This lets the healthcare providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.
Global Syndromic Multiplex Diagnostic Market Dynamics
Drivers
- Rising Incidence of Infectious Diseases
The increasing prevalence of infectious diseases, including respiratory infections and sexually transmitted diseases, is a significant driver. Syndromic multiplex diagnostic tests enable the simultaneous detection of various pathogens, aiding in the prompt identification and treatment of infections.
- Demand for Rapid and Accurate Diagnostics
There is a growing demand for diagnostic tools that offer quick and accurate results, particularly in emergency settings. Syndromic multiplex diagnostics fulfill this need by providing a comprehensive analysis of multiple pathogens in a single test, reducing the time required for diagnosis.
- Advancements in Diagnostic Technologies
Ongoing advancements in diagnostic technologies, such as nucleic acid amplification techniques and microarray technologies, contribute to the improved performance and accuracy of syndromic multiplex diagnostics, driving market growth.
Opportunities
- Emergence of Point-of-Care Testing
The increasing focus on point-of-care testing presents an opportunity for syndromic multiplex diagnostics. Portable and user-friendly diagnostic devices that can deliver rapid results at the point of care have the potential to enhance the adoption of multiplex testing.
- Integration with Electronic Health Records (EHR)
The integration of syndromic multiplex diagnostic data with electronic health records offers opportunities for better patient management and comprehensive healthcare decision-making.
Restraints/Challenges
- High Cost of Multiplex Diagnostic Tests
The cost associated with developing and conducting multiplex diagnostic tests can be a significant challenge. High expenses may limit their accessibility, especially in resource-constrained healthcare settings
-
Complexity in Data Interpretation
The interpretation of results from multiplex diagnostic tests can be complex, requiring trained professionals. This complexity may pose a challenge, particularly in regions with a shortage of skilled healthcare personnel.
Global Syndromic Multiplex Diagnostic Market Scope
The syndromic multiplex diagnostic market is segmented on the basis of product and services, infection type, disease, panels type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Reagents & Consumables
- Instruments
- Software & Accessories
- Services
Infection Type
- Viral
- Bacterial
- Parasites
- Fungal
Disease
- Respiratory Infection
- Gastroenteritis
- Sexually Transmitted Infections
- Sepsis
- Meningitis
- Others
Panels Type
- Respiratory Panel
- GI-Enteric Panel
- Sexually Transmitted Disease Panel
- Blood-Sepsis Panel
- Meningitis Panel
- Others
End User
- Hospitals
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Others
Global Syndromic Multiplex Diagnostic Market Regional Analysis/Insights
The syndromic multiplex diagnostic market is analyzed and market size insights and trends are provided based on product and services, infection type, disease, panels type and end user.
The regions covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Switzerland, Russia, Turkey, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines and rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa.
North America is expected to dominate the market and show the fastest growth due to the region's high healthcare expenditure and the increasing awareness about the syndromic multiplex diagnostic.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Syndromic Multiplex Diagnostic Market Share Analysis
The syndromic multiplex diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to syndromic multiplex diagnostic market.
Some of the major players operating in the syndromic multiplex diagnostic market are:
- BioFire Diagnostics (A Subsidiary of bioMérieux SA)
- Seegene Inc. (South Korea)
- Luminex Corporation. A DiaSorin Company (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- BD (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Cepheid (A subsidiary of Danaher (U.S.))
- QIAGEN (Germany)
- Abbott (U.S.)
- Hologic, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
- Akonni Biosystems, Inc. (U.S.)
- Biocartis (Belgium)
- QuantuMDx Group Ltd. (U.K.)
- Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany)
- Applied BioCode, Inc. (U.S.)
- Prominex Inc. (U.S.)
- Nanomix, Inc. (U.S.)
- Curetis (A subsidiary of OpGen, Inc.) (Germany)
- MiRXES Pte Ltd (Singapore)
SKU-